Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue SUPPL. 1, 2000, Pages

  Walenga, J M ^a   Jeske, W P ^a   Messmore, H L ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Heparin; Platelets; Thrombocytopenia; Thrombosis

Indexed keywords

ANTIBODY; COMPLEMENT; CYTOKINE; HEPARIN; PHOSPHOLIPID; THROMBIN;

ANTIGEN BINDING; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL INTERACTION; COMPLEMENT ACTIVATION; CRITICAL ILLNESS; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; ENDOTHELIUM INJURY; GENETIC ASSOCIATION; HUMAN; HYPERCOAGULABILITY; IMMUNE RESPONSE; LEUKOCYTE ACTIVATION; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; VEIN THROMBOSIS; VENOUS STASIS;

ANTICOAGULANTS; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; PLATELET ACTIVATION; RISK FACTORS; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS;

EID: 0034499530     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Arterial embolism occurring during systemic heparin therapy
2. Heparin: A cause of arterial emboli?
3. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
4. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
5. A 14-year study of heparin-induced thrombocytopenia
6. Heparin-induced thrombocytopenia: Historical review
7. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia
8. Massive acute thrombosis of the descending thoracic aorta in heparin-associated thrombocytopenia and thrombosis
9. Heparin-induced thrombocytopenia
10. PF4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
11. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets
12. HIT: Isolation of the antibody and characterization of a multi-molecular PF4-heparin complex as the major antigen
13. Heparin-induced thrombocytopenia: Laboratory studies
14. Insights into heparin-induced thrombocytopenia
15. Heparin-induced thrombocytopenia: Understanding improves but questions remain
16. Platelet binding of IgG from patients with heparin-induced thrombocytopenia
17. Fc RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with HIT
18. On the role of platelet Fc RIIa a phenotype in heparin-induced thrombocytopenia
19. Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia
20. 1 heparin-dependent antibodies: Explanation of predominance of Fc RIIa 'low responder' (His 131) gene in patients with heparin-induced thrombocytopenia
21. Laboratory tests for heparin-induced thrombocytopenia: A multicenter study
22. 2+ signaling
23. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets
24. Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents
25. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia
26. A diagnostic test for heparin-induced thrombocytopenia. Detection of platelet microparticles using flow cytometry
27. Determination of heparin-induced thrombocytopenia: A rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation
28. Serum-induced platelet procoagulant activity: An assay for the characterization of prothrombotic disorders
29. The release mechanism of platelet-activating factor during shear-stress induced platelet aggregation
30. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes
31. Platelet microparticles bind, activate and aggregate neutrophils in vitro
32. Platelet-derived microparticles associate with fibrin during thrombosis
33. Neutrophil-platelet adhesion: Relative roles of platelet P-selection and neutrophil β2 (ced18) integrins
34. Are leukocytes important for platelet activation in heparin-induced
35. A global view on the role of monocytes and platelets in atherogenesis
36. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets
37. 12-Hydroxyeicosatetraenoic acid upregulates P-selectin-induced tissue factor activity on monocytes
38. The biology of P-selectin glycoprotein ligand-1: Its role as a selectin counter-receptor in leukocyte-endothelial and leukocyte-platelet interaction
39. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome
40. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
41. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant
42. The procoagulant activity of red blood cells from patients with severe preeclampsia
43. Interactions of neutrophils and coagulation proteins
44. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia: A prospective, historical controlled study
45. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study
46. Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications
47. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from HIT patients
48. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT
49. Heparin-associated thrombocytopenia
50. P-selectin-β2-integrin cross-talk: A molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage
51. Mechanisms of cellular activation by platelet microparticles
52. Activated platelets induced monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells
53. Immune endothelial-cell injury in HIT
54. Effect of SR121566A, a potent GPIIb/IIIa antagonist on the HIT serum/heparin induced platelet mediated activation of endothelial cells
55. HIT anti-PF4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells
56. Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation
57. Platelet aggregation in heparin-induced thrombocytopenia is dependent on complement activation
58. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia
59. Procoagulant expression in platelets and defects leading to clinical disorders
60. Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia
61. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies
62. Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome
63. Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia
64. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
65. Heparin-associated thrombosis despite normal platelet counts
66. Thrombosis and inflammation as multicellular processes: Significance of cell-cell interactions
67. P-selectin induction of tissue factor biosynthesis and expression